Russia Invasion Requires Immediate Sanctions and Massive American Reindustrialization
China-Russia axis poses serious threat to U.S. national and economic security.
A Look at the Potential Sanctions Toolkit Against Russia and China
To sidestep the business communities concern over sanctions, Washington must include moves to re-industrialize. If not, U.S. rivals can easily choke supply chains.
China is Still Getting Away with IP Theft
The U.S. China Economic and Security Review Commission recently heard from 9 panelists who all agreed: China is still stealing intellectual property.
Importers File Bogus Requests for Section 301 Trade Exclusions
A look at some of the companies seeking Section 301 tariff exclusions. Companies that are merely Made in China distributors should not be given any breaks.
China Failed to Meet Phase I Trade Deal; Why is Congress Pushing for More Imports?
Over the last two months, over 100 members of Congress from both parties have called for the removal or weakening of China import tariffs.
Japan Steel Deal Removes Tariffs, Sets Import Limits
The Section 232s received another makeover. This time in Japan. The deal removes tariffs but caps what they can export to the U.S. and includes previously exempt volumes in the new tariff rate quota.
Notes from a Hearing: “The Beijing Olympics and the Faces of Repression”
The Congressional-Executive Commission on China says American corporations are ‘complicit’ in China’s human rights violations.
Goods Trade Deficit Tops $1 Trillion, Equivalent The Size of the Mexican Economy
The U.S. broke the trade deficit sound barrier in 2021, hitting $1.09 trillion. Why tariff policy isn’t enough to stem the tide of imports.
Vanguard, BlackRock Invested in Olympics Sportswear Company Tied to China Prison Labor
The Olympics are showing why we need capital market sanctions against China’s human rights abusers. Americans can’t buy Anta Sports gear if made from Xinjiang cotton. So why can Wall Street buy Anta’s shares?
House Hearing on FDA: Advanced Manufacturing May – or May Not – Lead to Domestic Manufacturing Boom
The House Committee on Energy and Commerce discussed FDA’s user fee budget and what can be done to reshore more of the pharmaceutical industry.
